Palisade Bio, Inc. (PALI) Fair Value 2026

PALI · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.2 /10

32 fundamental signals · 0 models active

Value Trap Risk

WARN (47/100)

Quick Summary — As of 2026-08-28, Palisade Bio, Inc. (PALI) trades at $2.00. QOC: 4.2/10. Value Trap Risk: 47/100 (WARN). 0/13 models active.

Key Facts

Ticker
PALI
Price
$2.00
Quality Score
4.2/10
Value Trap Risk
47/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Value Trap score of 47 suggests caution despite apparent undervaluation

What Fair Value Does Each Model Give PALI?

0 Intrinsic Value Models vs. Current Price ($2.00)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Palisade Bio, Inc. (PALI) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Palisade Bio, Inc. currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About PALI?

0 of 13 models are currently active for PALI. See which stocks rank higher →

How Does PALI Rank in Biotechnology?

Among 625 Biotechnology stocks, PALI ranks #500 by Quality of Company score. CirclFi's QOC score of 4.2/10 evaluates 32 fundamental signals. A score of 4.2 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotech businesses. For Palisade Bio, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is PALI a Value Trap?

CirclFi's Value Trap algorithm assigns PALI a score of 47/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Palisade Bio, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Palisade Bio, Inc. scores 4.2 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every PALI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Palisade Bio, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

INDPIndaptus Therapeutics, Inc.QOC 4.3GUTSFractyl Health, Inc.QOC 4.2PASGPassage Bio, Inc.QOC 4.3SANASana Biotechnology, Inc.QOC 4.2DCOYDecoy Therapeutics Inc.QOC 4.3NVCTNuvectis Pharma, Inc.QOC 4.2KRYSKrystal Biotech, Inc.QOC 7.8ENTXEntera Bio Ltd.QOC 5.7LXEOLexeo Therapeutics, Inc.QOC 4.9EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: INDP · GUTS · PASG · SANA · DCOY · NVCT · KRYS · ENTX · LXEO · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to PALI?

5 companies across all industries closest to PALI’s Quality of Company score of 4.2/10.

BUDZWEED, Inc.QOC 4.2FEAV5E Advanced Materials, Inc.QOC 4.2HNOIHNO International, Inc.QOC 4.2SDSTStardust Power Inc.QOC 4.2NVDANVIDIA CorporationQOC 10.0

Read investment analysis: BUDZ · FEAV · HNOI · SDST · NVDA

Where Does PALI Sit in CirclFi's Biotechnology Rankings?

PALI is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Palisade Bio, Inc.’s Valuation?

What is Palisade Bio, Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Palisade Bio, Inc. (PALI). The Quality of Company score is 4.2/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is PALI overvalued or undervalued right now?

At $2.00, 0 of 0 active models suggest PALI may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Palisade Bio, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.2 mean for PALI?

Palisade Bio, Inc.'s QOC of 4.2/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on PALI?

CirclFi analyzes PALI with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is PALI a value trap in 2026?

Palisade Bio, Inc.'s Value Trap score is 47/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Palisade Bio, Inc. (PALI) a Quality of Company score of 4.2/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/PALI/ · Methodology
Primary sources for this PALI valuation
  • Financial statements: Palisade Bio, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001357459) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for PALI as of ; valuations recomputed .